

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 9, 2026

Company name: TOREX SEMICONDUCTOR LTD.  
Name of representative: Takeshi Kimura, Representative  
Director and President  
(Securities code: 6616; Prime Market  
of the Tokyo Stock Exchange)  
Inquiries: Takashi Maegawa, Director, Corporate  
Officer and General Manager of  
Corporate Planning Headquarters  
(Telephone: +81-3-6222-2875)

### Notice Revision of Full-Year Earnings Forecast for FY2026

Based on recent performance trends, TOREX SEMICONDUCTOR LTD. (the “Company”) hereby announces that it has revised its full-year earnings forecast, originally announced on November 14, 2025, as follows.

1. Revision to Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending March 2026 (April 1, 2025 to March 31, 2026)

	Sales	Operating Profit	Ordinary Profit	Net Income Attributable to Owners of the Parent	Earnings Per Share
	Million Yen	Million Yen	Million Yen	Million Yen	Yen Sen
Previous Forecast (A)	24,500	600	600	400	39.65
<b>Revised Forecast (B)</b>	<b>25,000</b>	<b>800</b>	<b>800</b>	<b>550</b>	<b>51.88</b>
Change (B-A)	500	200	200	150	
Change Rate (%)	2.0%	33.3%	33.3%	37.5%	
(Reference) Previous Year Actual (FY2025)	23,957	△632	△820	△2,358	△214.62

#### 2. Reasons for Revision

With respect to the business outlook for the fiscal year ending March 2026, as of November 14, 2025, we had revised upward profits at each level from operating income onward, as initiatives to reduce expenses were implemented ahead of schedule. On the other hand, net sales were revised downward, as although inventory adjustments within the supply chain were moving toward resolution and new signs of activity had begun to emerge, we judged that the pace of recovery remained limited.

However, regarding net sales, we have recently observed strengthening momentum leading to new orders at both Torex and Phenitec, and we have determined that the recovery in net sales has become more certain. As a result, we have revised upward the forecast for net sales and, in anticipation of improved profitability associated with increased sales, have also revised upward profits at each level from operating income onward.

(Note) The above forecasts are based on information available as of the date of this document's release. Actual results may differ from these forecasts due to various factors in the future.